December 02, 2022
The Federal Circuit on Friday declined to review en banc a panel's decision that three Stanford University diagnostic patents licensed to a developer of commercial tests for kidney transplant rejections are ineligible for protection.
July 18, 2022
The Federal Circuit on Monday refused to undo a lower court's finding that three Stanford University patents licensed to a developer of commercial tests for kidney transplant rejections were invalid, saying they are directed toward natural phenomena.